TwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing Patent

The USPTO confirmed the patentability of all 23 claims in TwinStrand Biosciences’ U.S. Patent No. 10,287,631, one of two foundational Duplex Sequencing patents involved in its infringement litigation against Guardant Health. The announcement cites a November 4, 2026 Notice of Intent to Issue an Ex Parte Reexamination Certificate; it does not establish that the litigation is resolved.

Analysis

The key market implication is a higher legal-risk premium for Guardant Health, not yet a quantified change to its operating outlook. The USPTO action strengthens TwinStrand’s position on one foundational patent, but does not itself establish infringement, determine claim scope in the litigation, resolve the second patent, or specify remedies. The economic exposure therefore depends on whether the claims cover Guardant’s commercial workflows and whether any eventual remedy would require a license, redesign, or product limitation.

Near term, expect headline-driven volatility rather than a reliable estimate of earnings impact. Over the next 1–3 months, the useful catalysts are the reexamination certificate’s issuance and litigation developments that clarify claim construction, accused products, or potential remedies. A material adverse ruling could raise perceived licensing or redesign costs and pressure GH’s multiple; a favorable ruling for Guardant, narrow claim scope, or evidence that key products do not use the protected methods would unwind the risk premium. Over 6–18 months, the larger issue is whether intellectual-property uncertainty affects adoption or product development in precision oncology diagnostics—not a broad read-through to all sequencing companies. TwinStrand may gain negotiating leverage, but patentability alone does not establish commercial value. The announcement is a litigant’s framing; verify the USPTO record and court docket before treating it as a durable change in probability.

Key Decisions for Investors

• Do not initiate a standalone GH short solely on this procedural update: the potential liability and timing are unquantified, and the finding is not an infringement judgment. Treat it as an event-risk watch item.
• For existing GH exposure, review position sizing against litigation-gap risk; consider a defined-risk hedge only if the position is material and options pricing is reasonable. Avoid paying up for short-dated protection before confirming the next court or USPTO catalyst.
• Track the certificate, claim construction, accused-product mapping, and any remedy or licensing disclosures. Reassess bearish exposure if court findings connect the claims to commercially important Guardant products; reduce the risk thesis if claims are narrowed or the products are found outside their scope.
• Do not infer broad peer or sector impact yet. Any read-through to other diagnostics companies depends on their use of the specific patented methods, which the available information does not establish.